1800 Owens Street
Suite 900
San Francisco, CA 94158
United States
415 906 4324
https://www.vir.bio
Sector(s): Healthcare
Industry: Biotechnology
Full-time employees: 587
Name | Title | Pay | Exercised | Year born |
---|---|---|---|---|
Dr. Marianne De Backer M.B.A., M.Sc., Ph.D. | CEO & Director | 4.47M | N/A | 1969 |
Mr. Sung H. Lee | Executive VP & CFO | 968.45k | N/A | 1970 |
Dr. Ann M. Hanly Ph.D. | Executive VP & Chief Technology Officer | 896.07k | N/A | 1970 |
Dr. Jeff Calcagno M.D. | Executive VP & Chief Business Officer | 860.49k | N/A | 1961 |
Dr. Klaus Frueh Ph.D. | Co-Founder & Scientific Advisor | 177.66k | N/A | 1960 |
Dr. Lawrence Corey M.D. | Co-Founder & Scientific Advisor | N/A | N/A | 1948 |
Dr. Louis J. Picker M.D. | Co-Founder & Scientific Advisor | N/A | N/A | N/A |
Dr. Jennifer Eileen Towne Ph.D. | Executive VP & Chief Scientific Officer | N/A | N/A | N/A |
Ms. Heather Rowe Armstrong | Vice President of Investor Relations | N/A | N/A | N/A |
Ms. Vanina De Verneuil J.D. | Executive VP, General Counsel & Corporate Secretary | N/A | N/A | N/A |
Vir Biotechnology, Inc., a commercial-stage immunology company, develops therapeutic products to treat and prevent serious infectious diseases. It offers tobevibart + elebsiran for the treatment of chronic hepatitis delta; elebsiran + PEG-IFN-a, tobevibart ± elebsiran ± PEG-IFN-a, and elebsiran+ TLR8+PD-1 for the treatment of chronic hepatitis B; VIR-1388 and Cure mAb combination for the treatment of human immunodeficiency virus; VIR-8190 for the treatment of respiratory syncytial virus / human metapneumovirus; VIR-2981 for the treatment of influenza; VIR-1949 for the treatment of pre-cancerous HPV lesions; and VIR07229 and Sotrovimab for the treatment of COVID-19 infection under the Xevudy brand. The company has grant agreements with Bill & Melinda Gates Foundation and National Institutes of Health; an option and license agreement with Brii Biosciences Limited; a collaboration and license agreement with Alnylam Pharmaceuticals, Inc.; license agreements with MedImmune; collaboration with WuXi Biologics and Glaxo Wellcome UK Ltd.; and a collaborative research agreement with GlaxoSmithKline Biologicals SA. It also has a manufacturing agreement with Samsung Biologics Co.,Ltd. for the manufacture of SARS-COV-2 antibodies. The company was incorporated in 2016 and is headquartered in San Francisco, California.
Vir Biotechnology, Inc.’s ISS governance QualityScore as of 1 May 2024 is 7. The pillar scores are Audit: 6; Board: 4; Shareholder rights: 8; Compensation: 8.